MedTrace Logo

"Transarterial Microembolization (TAME) in Inflammatory Knee Pathology"

NCT07140367 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2026-04-07

No results posted yet for this study

Summary

Patients with knee OA and chronic pain refractory to at least 3 months of conventional conservative therapy will be included in the study, which will evaluate the clinical results obtained after treatment with selective arterial embolization (selection and enrollment, treatment with selective arterial embolization, follow-up checks). Forty-three patients will be included in the study and will undergo the transarterial microembolization procedure after signing the informed consent form for participation in the study and the collection of anamnestic data. Subsequently, patients will be followed up with clinical evaluation at 1, 3, 6, 12, and 24 months of follow-up or until possible dropout for other treatment.

Conditions

  • Inflammatory Articular Diseases
  • Knee Osteoarthristis

Interventions

PROCEDURE

Transarterial Microembolization

Identification of the hypervascularization of the knee. Selective and super-selective catheterization of pathological genicular arterial branches, through the use of micro-catheters. - Injection of embolizing material (Nexsphere-F - Kardia) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).

Sponsors & Collaborators

  • Ospedale San Giuseppe Moscati, Avellino

    collaborator UNKNOWN

  • Azienda Ospedaliero-Universitaria, Catania

    collaborator UNKNOWN

  • Azienda Ospedaliera di Perugia

    collaborator OTHER

  • San Salvatore Hospital, AST Pesaro-Urbino

    collaborator OTHER

  • A.O.U. Città della Salute e della Scienza - Molinette Hospital

    collaborator OTHER

  • Istituto Ortopedico Rizzoli

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2029-09-01
Completion
2031-09-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140367 on ClinicalTrials.gov